Technical Analysis for CYTO - Altamira Therapeutics Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.43 | -3.39% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | -3.39% | |
| Calm After Storm | Range Contraction | -3.39% | |
| NR7 | Range Contraction | -3.39% | |
| Inside Day | Range Contraction | -3.39% | |
| Oversold Stochastic | Weakness | -3.39% | |
| New 52 Week Closing Low | Bearish | 3.26% | |
| Calm After Storm | Range Contraction | 3.26% | |
| Wide Bands | Range Expansion | 3.26% | |
| Lower Bollinger Band Touch | Weakness | 3.26% | |
| Oversold Stochastic | Weakness | 3.26% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Gap Down Partially Closed | about 3 hours ago |
| Fell Below Lower Bollinger Band | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Lower Bollinger Band Support | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 09/10/2024
Altamira Therapeutics Ltd. Description
Altamira Therapeutics is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Allergy Nervous System Otology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.2 |
| 52 Week Low | 0.4 |
| Average Volume | 85,980 |
| 200-Day Moving Average | 1.24 |
| 50-Day Moving Average | 0.58 |
| 20-Day Moving Average | 0.48 |
| 10-Day Moving Average | 0.45 |
| Average True Range | 0.06 |
| RSI (14) | 36.71 |
| ADX | 36.0 |
| +DI | 16.21 |
| -DI | 20.15 |
| Chandelier Exit (Long, 3 ATRs) | 0.45 |
| Chandelier Exit (Short, 3 ATRs) | 0.57 |
| Upper Bollinger Bands | 0.54 |
| Lower Bollinger Band | 0.41 |
| Percent B (%b) | 0.23 |
| BandWidth | 28.52 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.49 | ||||
| Resistance 3 (R3) | 0.49 | 0.47 | 0.48 | ||
| Resistance 2 (R2) | 0.47 | 0.45 | 0.47 | 0.48 | |
| Resistance 1 (R1) | 0.45 | 0.44 | 0.46 | 0.46 | 0.48 |
| Pivot Point | 0.43 | 0.43 | 0.44 | 0.43 | 0.43 |
| Support 1 (S1) | 0.42 | 0.42 | 0.43 | 0.42 | 0.40 |
| Support 2 (S2) | 0.40 | 0.41 | 0.40 | 0.40 | |
| Support 3 (S3) | 0.39 | 0.40 | 0.40 | ||
| Support 4 (S4) | 0.39 |
